Figure 4.

Enhanced OVA-induced airway inflammation by IRAK-M KO BMDCs. (A) Schematic representation of the experimental protocol used for adoptive transfer of OVA-treated WT or IRAK-M KO BMDCs to WT mice. (B) Representative images of hematoxylin and eosin staining and (C) semiquantitative histopathological scores of OVA-exposed WT mouse lungs that received PBS or transfer of WT or IRAK-M KO BMDCs. n = 10 mice in each group; *P < 0.05. (D) Total inflammatory cell counts in BAL fluid and lung, and percentages of eosinophils in BAL fluid from OVA-treated WT mice that received PBS or WT or IRAK-M KO bone marrow–derived macrophages (BMDMs). n = 10 animals in each group; *P < 0.05. (E) Flow cytometry analysis of T cell subpopulations in whole-lung tissue from OVA-treated WT mice adoptively transferred with PBS or WT or IRKA-M KO BMDCs. n = 10 animals in each group; *P < 0.05. i.t., intratracheal; RORC, retinoic acid-related orphan receptor C.